[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse CXCL9

Summary
SymbolCXCL9
Namechemokine (C-X-C motif) ligand 9
Aliases SCYB9; Humig; crg-10; MIG; monokine induced by gamma interferon; gamma-interferon-induced monokine; monokine ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00048 Small cytokines (intecrine/chemokine)
Function

Cytokine that affects the growth, movement, or activation state of cells that participate in immune and inflammatory response. Chemotactic for activated T-cells. Binds to CXCR3.

> Gene Ontology
 
Biological Process GO:0000768 syncytium formation by plasma membrane fusion
GO:0002237 response to molecule of bacterial origin
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0006140 regulation of nucleotide metabolic process
GO:0006816 calcium ion transport
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006949 syncytium formation
GO:0006968 cellular defense response
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0007520 myoblast fusion
GO:0009150 purine ribonucleotide metabolic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009615 response to virus
GO:0010522 regulation of calcium ion transport into cytosol
GO:0010524 positive regulation of calcium ion transport into cytosol
GO:0010830 regulation of myotube differentiation
GO:0010831 positive regulation of myotube differentiation
GO:0010959 regulation of metal ion transport
GO:0014902 myotube differentiation
GO:0019932 second-messenger-mediated signaling
GO:0019933 cAMP-mediated signaling
GO:0019935 cyclic-nucleotide-mediated signaling
GO:0030335 positive regulation of cell migration
GO:0030595 leukocyte chemotaxis
GO:0030799 regulation of cyclic nucleotide metabolic process
GO:0030801 positive regulation of cyclic nucleotide metabolic process
GO:0030814 regulation of cAMP metabolic process
GO:0030816 positive regulation of cAMP metabolic process
GO:0032103 positive regulation of response to external stimulus
GO:0032496 response to lipopolysaccharide
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0032846 positive regulation of homeostatic process
GO:0034762 regulation of transmembrane transport
GO:0034764 positive regulation of transmembrane transport
GO:0034765 regulation of ion transmembrane transport
GO:0034767 positive regulation of ion transmembrane transport
GO:0040017 positive regulation of locomotion
GO:0042692 muscle cell differentiation
GO:0043270 positive regulation of ion transport
GO:0043949 regulation of cAMP-mediated signaling
GO:0043950 positive regulation of cAMP-mediated signaling
GO:0045445 myoblast differentiation
GO:0045661 regulation of myoblast differentiation
GO:0045663 positive regulation of myoblast differentiation
GO:0045981 positive regulation of nucleotide metabolic process
GO:0046058 cAMP metabolic process
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051146 striated muscle cell differentiation
GO:0051147 regulation of muscle cell differentiation
GO:0051149 positive regulation of muscle cell differentiation
GO:0051153 regulation of striated muscle cell differentiation
GO:0051155 positive regulation of striated muscle cell differentiation
GO:0051208 sequestering of calcium ion
GO:0051209 release of sequestered calcium ion into cytosol
GO:0051235 maintenance of location
GO:0051238 sequestering of metal ion
GO:0051272 positive regulation of cellular component movement
GO:0051279 regulation of release of sequestered calcium ion into cytosol
GO:0051281 positive regulation of release of sequestered calcium ion into cytosol
GO:0051282 regulation of sequestering of calcium ion
GO:0051283 negative regulation of sequestering of calcium ion
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0051607 defense response to virus
GO:0051924 regulation of calcium ion transport
GO:0051928 positive regulation of calcium ion transport
GO:0055074 calcium ion homeostasis
GO:0060142 regulation of syncytium formation by plasma membrane fusion
GO:0060143 positive regulation of syncytium formation by plasma membrane fusion
GO:0060326 cell chemotaxis
GO:0060401 cytosolic calcium ion transport
GO:0060402 calcium ion transport into cytosol
GO:0070098 chemokine-mediated signaling pathway
GO:0070509 calcium ion import
GO:0070588 calcium ion transmembrane transport
GO:0070838 divalent metal ion transport
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
GO:0090279 regulation of calcium ion import
GO:0090280 positive regulation of calcium ion import
GO:0097553 calcium ion transmembrane import into cytosol
GO:0098542 defense response to other organism
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900544 positive regulation of purine nucleotide metabolic process
GO:1901739 regulation of myoblast fusion
GO:1901741 positive regulation of myoblast fusion
GO:1902656 calcium ion import into cytosol
GO:1903169 regulation of calcium ion transmembrane transport
GO:1904062 regulation of cation transmembrane transport
GO:1904064 positive regulation of cation transmembrane transport
GO:1904427 positive regulation of calcium ion transmembrane transport
GO:2000021 regulation of ion homeostasis
GO:2000147 positive regulation of cell motility
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0008009 chemokine activity
GO:0042379 chemokine receptor binding
GO:0045236 CXCR chemokine receptor binding
GO:0048248 CXCR3 chemokine receptor binding
Cellular Component GO:0009897 external side of plasma membrane
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04062 Chemokine signaling pathway
hsa04620 Toll-like receptor signaling pathway
Reactome R-HSA-380108: Chemokine receptors bind chemokines
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolCXCL9
Namechemokine (C-X-C motif) ligand 9
Aliases SCYB9; Humig; crg-10; MIG; monokine induced by gamma interferon; gamma-interferon-induced monokine; monokine ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CXCL9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CXCL9 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26567139Colon CarcinomaPromote immunity (infiltration)We found that PRC2 components and demethylase JMJD3-mediated histone H3 lysine 27 trimethylation (H3K27me3) repress the expression and subsequent production of Th1-type chemokines CXCL9 and CXCL10, mediators of effector T-cell trafficking. Moreover, the expression levels of PRC2 components, including EZH2, SUZ12, and EED, were inversely associated with those of CD4, CD8, and Th1-type chemokines in human colon cancer tissue, and this expression pattern was significantly associated with patient survival.
26503055Ovarian CarcinomaPromote immunity (infiltration)Using human ovarian cancers as our model, here we show that enhancer of zeste homologue 2 (EZH2)-mediated histone H3 lysine 27 trimethylation (H3K27me3) and DNA methyltransferase 1 (DNMT1)-mediated DNA methylation repress the tumour production of T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, and subsequently determine effector T-cell trafficking to the tumour microenvironment.
27070705Colorectal CarcinomaPromote immunity (infiltration)While two distinct subsets of myeloid cells induce an influx of T cells into the invasive margin via CXCL9/CXCL10, CCL5 is produced by these T cells and stimulates pro-tumoral effects via CCR5.
26109379MelanomaPromote immunity (infiltration)These studies unexpectedly reveal a non-redundant requirement for the CXCR3-CXCL9/CXCL10 axis for CD8+ T cell trafficking within the intravascular space that could not be predicted from static profiling of intratumoral chemokines or their receptors on T cells.
25754875Colorectal CarcinomaPromote immunity (infiltration)We also demonstrate a selective increase of the chemokines CXCL9 and CXCL10 in Treg-cell-depleted tumors, which were accompanied by accumulation of CXCR3(+) T cells, and increased IFN-γ mRNA expression.
25398437MelanomaPromote immunityHere we show how combining a senescence-inducing inhibitor of the mitotic kinase Aurora A (AURKA) with an MDM2 antagonist activates p53 in senescent tumors harboring wildtype 53. In the model studied, this effect is accompanied proliferation arrest, mitochondrial depolarization, apoptosis and immune clearance of cancer cells by antitumor leukocytes in a manner reliant upon CCL5, CCL1 and CXCL9.
28486109MelanomaPromote immunity (infiltration)Mechanistically, this was due to the absence of CXCL9/10, which we found to be produced by CD103+dendritic cells (DCs) in T?cell-inflamed tumors. Our data indicate that lack of CD103+DCs within the tumor microenvironment dominantly resists the effector phase of an anti-tumor T?cell response, contributing to immune escape.
19470694Ovarian CarcinomaPromote immunity (infiltration)Furthermore, through synergistic action between IL-17 and interferon-gamma, Th17 cells stimulate CXCL9 and CXCL10 production to recruit effector T cells to the tumor microenvironment. The levels of CXCL9 and CXCL10 are associated with tumor-infiltrating effector T cells. The levels of tumor-infiltrating Th17 cells and the levels of ascites IL-17 are reduced in more advanced diseases and positively predict patient outcome.
22333315Breast CarcinomaPromote immunity (infiltration)In murine breast cancer models, the two interferon-gamma (IFN-γ) inducible chemokines and CXC-chemokine receptor 3 (CXCR3) receptor ligands, monokine induced by γ-interferon (CXCL9) and interferon-γ-inducible protein-10 (CXCL10) impair tumor growth and metastasis formation through recruitment of natural killer (NK) cells and tumor-suppressive T lymphocytes.
24893628Skin Basal Cell CarcinomaPromote immunity (infiltration)Intravaginal imiquimod deposition induced upregulation of CXCL9 and CXCL10 mRNA expression in the genital tract, which are produced in response to IFNγ receptor signaling and attract cells expressing their ligand, CXCR3.
29671006Colon CarcinomaPromote immunity (infiltration)Treg depletion also resulted in increased levels of the chemokines CXCL9 and CXCL10 specifically in the tumors.
24004819Breast CarcinomaPromote immunity (infiltration)Enhanced immune surveillance in COX-2(MEC)KO tumors was coincident with increased intratumoral CXCL9, a T cell chemoattractant, and decreased expression of T lymphocyte co-inhibitory receptors CTLA4 and PD-1, as well as PD-L1, the ligand for PD-1.
23843024Breast CarcinomaPromote immunity (infiltration)Furthermore, Stat1-deficiency resulted in reduced expression of the T-cell chemotactic factors CXCL9, CXCL10, and CXCL11 in the tumor epithelium.
25092771colon carcinomaPromote immunityThis combination therapy also increased TILs, including tumor antigen-specific CD8 T cells, and elevated the expression of activation markers FAS-L, CXCL-9, CD31, and CD105 in MDSCs and TAMs, leading to reduced tumor volumes and an increase in the number of tumor-free animals.
23241877fibrosarcomaPromote immunityRemarkably, the ability of Mig-deficient tumor cells to express another CXCR3 ligand, CXCL10/IFN-gamma-inducible protein, does not compensate for the absent antitumor functions of Mig, suggesting a nonredundant role for this chemokine in the suppression of tumor growth.
21949133Lung CarcinomaPromote immunityIncreased apoptosis, the induction of cytokines (IFN-γ and IL-12) and chemokines (CXCL9 and CXCL10), and the elevation of leukocyte markers (CD11b, CD11c, CD4, and CD8) were detected at tumor sites in C3H/HeN mice but not in C3H/HeJ mice
Summary
SymbolCXCL9
Namechemokine (C-X-C motif) ligand 9
Aliases SCYB9; Humig; crg-10; MIG; monokine induced by gamma interferon; gamma-interferon-induced monokine; monokine ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CXCL9 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA Sensitive to T cell-mediated killing
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCXCL9
Namechemokine (C-X-C motif) ligand 9
Aliases SCYB9; Humig; crg-10; MIG; monokine induced by gamma interferon; gamma-interferon-induced monokine; monokine ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CXCL9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1220.896
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3960.878
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4960.796
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.9350.352
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.9910.207
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3970.834
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.3730.0853
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.9180.295
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.7210.732
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 482.020.283
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.9810.506
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682301.2940.000485
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CXCL9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCXCL9
Namechemokine (C-X-C motif) ligand 9
Aliases SCYB9; Humig; crg-10; MIG; monokine induced by gamma interferon; gamma-interferon-induced monokine; monokine ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CXCL9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCXCL9
Namechemokine (C-X-C motif) ligand 9
Aliases SCYB9; Humig; crg-10; MIG; monokine induced by gamma interferon; gamma-interferon-induced monokine; monokine ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CXCL9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CXCL9.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCXCL9
Namechemokine (C-X-C motif) ligand 9
Aliases SCYB9; Humig; crg-10; MIG; monokine induced by gamma interferon; gamma-interferon-induced monokine; monokine ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CXCL9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCXCL9
Namechemokine (C-X-C motif) ligand 9
Aliases SCYB9; Humig; crg-10; MIG; monokine induced by gamma interferon; gamma-interferon-induced monokine; monokine ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CXCL9 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCXCL9
Namechemokine (C-X-C motif) ligand 9
Aliases SCYB9; Humig; crg-10; MIG; monokine induced by gamma interferon; gamma-interferon-induced monokine; monokine ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CXCL9 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCXCL9
Namechemokine (C-X-C motif) ligand 9
Aliases SCYB9; Humig; crg-10; MIG; monokine induced by gamma interferon; gamma-interferon-induced monokine; monokine ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CXCL9 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.